Plus, news about Biodexa Pharmaceuticals:
RevOpsis Therapeutics secures $16.5M seed round: The San Carlos, CA-based biotech will use the funds to complete IND-enabling studies for its lead candidate, RO-104, for neovascular age-related macular degeneration and hire key management staff. First-in-human studies of RO-104 are expected to start in 2025, the company said.
Pfizer and CeMM tout AI platform: Pfizer worked with the Austrian research center, CeMM Forschungszentrum für Molekulare Medizin, to scale a platform that enables them to measure “how hundreds of small molecules with various chemical structures interact with all expressed proteins in living cells.” The process has led to a catalog of tens of thousands of ligand-protein interactions that can now be used for drug discovery purposes.
Biodexa buys rights to orphan disease drug: The UK company purchased exclusive, worldwide rights to eRapa — an oral tablet formulation of mTOR inhibitor rapamycin — from Rapamycin Holdings for an undisclosed amount. eRapa is Phase 3 ready in familial adenomatous polyposis. The Cancer Prevention and Research Institute of Texas will pitch in $17 million for the trial.